Bioventix PLC (LON:BVXP - Get Free Report) passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of GBX 2,644.08 ($35.58) and traded as high as GBX 2,950 ($39.69). Bioventix shares last traded at GBX 2,950 ($39.69), with a volume of 27,357 shares changing hands.
Bioventix Stock Up 1.7%
The company has a market cap of £154.47 million, a PE ratio of 19.08 and a beta of 0.35. The firm's fifty day simple moving average is GBX 2,658.01 and its 200-day simple moving average is GBX 3,015.19.
Bioventix (LON:BVXP - Get Free Report) last announced its quarterly earnings results on Monday, March 31st. The biotechnology company reported GBX 72.27 ($0.97) earnings per share (EPS) for the quarter. Bioventix had a net margin of 59.51% and a return on equity of 69.09%. On average, analysts predict that Bioventix PLC will post 166.3066955 earnings per share for the current year.
Bioventix Cuts Dividend
The company also recently disclosed a dividend, which was paid on Friday, April 25th. Investors of record on Thursday, April 10th were paid a dividend of GBX 70 ($0.94) per share. This represents a dividend yield of 2.95%. The ex-dividend date was Thursday, April 10th. Bioventix's payout ratio is 102.19%.
Insider Activity at Bioventix
In related news, insider Bruce Hiscock purchased 31 shares of the business's stock in a transaction on Monday, April 28th. The shares were bought at an average price of GBX 2,632 ($35.41) per share, with a total value of £815.92 ($1,097.85). Insiders own 8.02% of the company's stock.
About Bioventix
(
Get Free Report)
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants.
See Also
Before you consider Bioventix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventix wasn't on the list.
While Bioventix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
